Abstract submission - terms & conditions
Abstract submission agreement – rules and policies
In submitting an abstract for consideration for the ESGCT 2021 Virtual Congress, the primary author is responsible for ensuring that work described in the abstract was conducted in accordance with the following rules and policies. All abstracts submitted are screened by the Organising Committee to ensure that the abstract:
- Includes substantive results
- Is not a clinical case study
- Does not promote a commercial product or service.
On occasion, the Organising Committee may solicit additional information from submitters to ensure that the work reported in an abstract complies with the Research Conduct Policy outlined below. Failure to reply satisfactorily to a request for additional information constitutes grounds for abstract rejection. While abstracts are evaluated for scientific interest and are citable, the brevity of the presentation precludes rigorous peer review. Thus, abstract acceptance should not be taken as endorsement of the validity or safety of research by the ESGCT, the Congress Partner Societies
or the Organising Committee.
1. Research Conduct Policy
Submission of an abstract constitutes a formal agreement and statement by the authors that they have conducted the reported research in accordance with the relevant institutional and national guidelines and regulations regarding experiments on human subjects, live vertebrates or higher invertebrates. Abstracts reporting any experimental work that was not conducted in accordance with these guidelines will be rejected by the Organising Committee.
2. Not Published Elsewhere
Abstracts must be based on results that have not been published in their entirety in any journal nationally or internationally, before submission to this meeting.
3. Identical Policy
Presentation material presented at the meeting must be substantively identical to that described in the abstract. In particular, the title, authorship, and scientific content of the presentation at the meeting must match that in the abstract.
4. Presentation limits
The first author should be designated as the presenting author and present the work at the meeting. No presentation may be given by an individual who is not an author on the abstract.
5. Author consent
Authors may not be listed on an abstract unless they have given their consent to the presenting author. All material must be the work of the authors listed.
6. Full disclosure of information
Transparency is vital for the open sharing of information. Full disclosure is required of the identities of genes, proteins, chemicals, active agents etc. in all presentations, both oral and poster.
7. Presentation agreement remuneration
Abstract submission implies an understanding that the authors will receive no remuneration from the ESGCT for participation other than that specified in writing by the Society.
8. Permission for use of name and likeness
Authors give the ESGCT, Congress Partner Societies, their agents and representatives the right to use their names and likeness in promotional and other material published in relation to the meeting.
9. Permission for publication of material
Authors grant the ESGCT and Congress Partner Societies copyright for publication of material they may provide for inclusion in the proceedings for the Congress. The copyright consists of any and all rights allowed by the copyright laws of all countries. Authors understand that the proceedings, including their contribution, will be made available in printed and/or electronic form to the attendees of the Congress, members of the ESGCT and Congress Partner Societies, and other interested parties pursuant to policies established by the ESGCT Board. Authors understand that the ESGCT will hold the copyright for the proceedings and its contents. Authors understand that the copyright of the compilation of materials in the proceedings is not the same as the copyright of an individual item of material included in the proceedings. Authors understand that authors are encouraged to include copyright notices as appropriate on all the materials submitted to the organisers for publication. Authors understand that the ESGCT and Congress Partner Societies take no responsibility for registering any copyright and advise authors to take all appropriate steps to do so. Authors authorise the ESGCT and Congress Partner Societies to sell or otherwise distribute said proceedings to their membership and general public. In return, Authors understand that the ESGCT and Congress Partner Societies retain the right to reprint their contribution in any publication. Authors affirm that their contribution contains no matter that is defamatory or is otherwise unlawful or invades individual privacy, or infringes on any proprietary right or statutory copyright. Authors affirm that their contribution is their own original or that they have obtained permission at their own expense from the copyright holder for publication and will submit documentation, showing permission for use, to the ESGCT at the time of submission of the materials to be distributed. Authors understand that the information contained in their submitted abstract may be shared with third-party processors when we do not have the in-house capacity required for certain functions (such as graphic design or printing).
: abstracts are published in all Congress attendees' online accounts from Day 1 of the Congress, and the official journal publication of the abstracts is available on the Human Gene Therapy website from Day 1 of the Congress. Please see our Congress Embargo Policy
for further details.
Authors agree to indemnify and hold harmless the ESGCT, Congress Partner Societies, their agents and representatives should the material presented or provided for publication be determined to defame, libel or slander an individual or organisation, violate the confidentiality of any individual or organisation, or infringe on another's copyright.
Submitting authors must agree to the above terms at time of submission.
These terms and conditions were updated on 07/04/2021.